Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

IMPORTANCE: Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in MAPK pathway activation. OBJECTIVE: To assess the efficacy of selumetinib, a selective, non-ATP competitive inhibitor of MEK1 and MEK2, in uveal melanoma. DESIGN: Randomized open-label phase II clinical trial co...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA
Asıl Yazarlar: Carvajal, Richard D., Sosman, Jeffrey A., Quevedo, Jorge Fernando, Milhem, Mohammed M., Joshua, Anthony Michael, Kudchadkar, Ragini R., Linette, Gerald P., Gajewski, Thomas F., Lutzky, Jose, Lawson, David H., Lao, Christopher D., Flynn, Patrick J., Albertini, Mark R., Sato, Takami, Lewis, Karl, Doyle, Austin, Ancell, Kristin, Panageas, Katherine S., Bluth, Mark, Hedvat, Cyrus, Erinjeri, Joseph, Ambrosini, Grazia, Marr, Brian, Abramson, David, Dickson, Mark Andrew, Wolchok, Jedd D., Chapman, Paul B., Schwartz, Gary K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249701/
https://ncbi.nlm.nih.gov/pubmed/24938562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2014.6096
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller